VT3989
vivace therapeutics
['mesothelioma', 'vt3989', 'solid tumor']
ct006 - first-in-class, first-in-human phase 1 trial of vt3989, an inhibitor of yap-tead, in patients with advanced solid tumors enriched for malignant mesothelioma and other tumors with nf2 mutations #aacr23 
L/S biotech. PhD student @UniofOxford